Meta-analysis Hints at Survival Benefit With LAP Monitoring in HFrEF
Researchers in this space are also starting to ask: is it time to put patients in charge of tracking and acting on pressure changes?
Related Articles
Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus | NEJM
Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular hemodynamic performance and associated adverse cardiovascular clinical outcomes after…
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – …
A Placebo-Controlled Trial of PCI for Stable Angina | NEJM
Correspondence from The New England Journal of Medicine — A Placebo-Controlled Trial of PCI for Stable Angina
Amylyx’s ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug
Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered…
Remembering Dr. Merrill Benson – Amyloidosis Research Consortium
The Amyloidosis Research Consortium extends our deepest, heartfelt condolences to the family and friends of Dr. Merrill Benson, world renowned amyloidosis expert, who passed away…
Pinak Shah, MD on X: “@djc795 @KadoshBernard @CMichaelGibson 👆🏽why I would not want another trial. Yes, could have done better (sham control). But we now have a therapy for a difficult problem that makes people feel better and is incredibly safe. Appropriate pt selection key and we have to…
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostPinak Shah, MD@PinakShahMDwhy I would not want another trial. Yes, could have done…
Longevity of the Placebo Effect in the Therapeutic Angiogenesis and Laser Myocardial Revascularization Trials in Patients With Coronary Heart Disease
The long-term beneficial effects of placebo therapy were evaluated in angiogenesis and laser myocardial revascularization trials in patients who had end-stage coronary heart disease. Improvements…
FDA Advisors Set to Take on TriClip for TR as TRILUMINATE Questions Loom
The executive summary questions the open-label trial, noting that benefit was driven by a softer QoL endpoint.
Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials
Congestion is a key driver of morbidity and mortality in heart failure. Implanted haemodynamic monitoring devices might allow early identification and management of congestion. Here,…
Breakthrough Devices Program
This guidance proposes select updates to the guidance that clarify how the program may be applicable to certain medical devices that provide for more effective…